Lactobacillus casei per Antibiotic-Associated Diarrhea (AAD)
C Evidenze Evidenza limitata da studi di piccole dimensioni, ma esistono alcuni segnali positivi.Some evidence for AAD prevention in hospitalized elderly patients (PLACIDE trial was negative for primary outcome but showed trends).
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dcasei\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
In sintesi
Some evidence for AAD prevention in hospitalized elderly patients (PLACIDE trial was negative for primary outcome but showed trends).
Key Study Findings
In Vitro
Complex probiotics alleviate ampicillin-induced antibiotic-associated diarrhea in mice.
Dose: 4-strain probiotic mixture
vs: Ampicillin-induced AAD model
Outcome: Gut microbiota recovery and immune modulation
Effetto: None
None
Popolazione: Ampicillin-induced AAD mouse model
Meta-Analysis
n=692
Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and …
Dose: None
vs: Control group
Outcome: the incidence rates of AAD and CDAD, and …
Effetto: OR 0.39,
None
Popolazione: Diarrhea patients
Randomized Controlled Trial
n=314
4.3 weeks
Double-blind
Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial.
Dose: None
vs: Placebo
Outcome: Bowel function
Effetto: None
p=0.30
Popolazione: None
Systematic Review
n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None
vs: None
Outcome: Diarrhea outcomes
Effetto: None
None
Popolazione: None
Controlled Clinical Trial
n=32
4.3 weeks
Open-label
Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic …
Dose: 10 billion L. casei, 2 bottles/day
vs: Contemporary matched controls
Outcome: Safety, feasibility, AAD incidence
Effetto: None
None
Popolazione: ICU patients on antibiotics
Meta-Analysis
n=9569
Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis.
Dose: None
vs: Placebo/no probiotic
Outcome: Prevention of antibiotic-associated diarrhea
Effetto: LGG OR 0.28 (0.17-0.47) for AAD prevention
None
Popolazione: Patients on antibiotics
Key Statistics
3
Studi
500
Partecipanti
↑
Positive
C
Grado
Referenced Papers
Frontiers in microbiology
2023
21 citazioni
Journal of digestive …
2020
43 citazioni
Journal of clinical …
2019
17 citazioni
Frontiers in medicine
2018
450 citazioni
United European gastroenterology …
2018
66 citazioni
Nutrients
2018
50 citazioni
F1000Research
2016
63 citazioni
Antibiotics (Basel, Switzerland)
2015
104 citazioni
Clinical infectious diseases …
2015
59 citazioni
World journal of …
2014
73 citazioni
Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea.
Other
Journal of medical …
2012
28 citazioni
Revista da Sociedade …
2012
13 citazioni
Journal of clinical …
2011
432 citazioni
The American journal …
2010
313 citazioni
Canadian journal of …
2007
182 citazioni
Acta paediatrica Taiwanica …
2004
6 citazioni
International journal of …
2000
181 citazioni
The Journal of …
1999
559 citazioni
Anaerobe
1997
40 citazioni
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 1-10 billion CFU/day
- aadprevention:
- 6.5 billion CFU/day (Shirota strain)
- immunesupport:
- 10 billion CFU/day
Limite massimo: Well-tolerated up to 20 billion CFU/day in clinical trials
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| 4-strain probiotic mixture | -- | Positive | -- |
| None | -- | Positive | 692 |
| None | 4.3 weeks | Neutral | 314 |
| None | -- | Mixed | 228 |
| 10 billion L. casei, 2 bottles/day | 4.3 weeks | Positive | 32 |
| None | -- | Positive | 9569 |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
Momento migliore per l'assunzione: With or without food; consistent daily timing recommended
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Rare dairy-related reactions in lactose-sensitive individuals
- ⚠ Very rare: bacteremia in immunocompromised individuals
Interazioni note
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
Livello di assunzione massimo tollerabile: Well-tolerated up to 20 billion CFU/day in clinical trials
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Lactobacillus casei help with Antibiotic-Associated Diarrhea (AAD)?
Based on 3 studies with 500 participants, there is limited but promising evidence that Lactobacillus casei may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is C (Some Evidence).
How much Lactobacillus casei should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus casei?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare dairy-related reactions in lactose-sensitive individuals, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus casei and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.
Related Evidence
Altri ingredienti per Antibiotic-Associated Diarrhea (AAD)
References
- [1] Wenwen Li et al.. Front Microbiol. 2023. Complex probiotics alleviate ampicillin-induced antibiotic-associated diarrhea in mice. doi:10.3389/fmicb.2023.1156058 PubMed
- [2] Yan Ma et al.. J Dig Dis. 2020. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. doi:10.1111/1751-2980.12839 PubMed
- [3] María Velasco et al.. J Clin Gastroenterol. 2019. Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial. doi:10.1097/MCG.0000000000001131 PubMed
- [4] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
- [5] Jiayi Cai et al.. United European Gastroenterol J. 2018. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. doi:10.1177/2050640617736987 PubMed
- [6] Cathy Alberda et al.. Nutrients. 2018. Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic Associated Diarrhea and Clostridium difficile. doi:10.3390/nu10050539 PubMed
- [7] Sunit C Singhi et al.. F1000Res. 2016. Probiotics in critically ill children. doi:10.12688/f1000research.7630.1 PubMed
- [8] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
- [9] Julie Auclair et al.. Clin Infect Dis. 2015. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of … doi:10.1093/cid/civ179 PubMed
- [10] Christoph G Dietrich et al.. World J Gastroenterol. 2014. Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea. doi:10.3748/wjg.v20.i42.15837 PubMed
- [11] Alvine Adrienne Kamdeu Fansi et al.. J Med Econ. 2012. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. doi:10.3111/13696998.2011.629015 PubMed
- [12] Daniela Nogueira Prado de Souza et al.. Rev Soc Bras Med Trop. 2012. The effect of Lactobacillus casei and Bifidobacterium breve on antibiotic-associated diarrhea treatment: randomized double-blind clinical trial. doi:10.1590/s0037-86822012000100021 PubMed
- [13] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
- [14] Xing Wang Gao et al.. Am J Gastroenterol. 2010. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium … doi:10.1038/ajg.2010.11 PubMed
- [15] M Beausoleil et al.. Can J Gastroenterol. 2007. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, … doi:10.1155/2007/720205 PubMed
- [16] Yu-Kung Chou et al.. Acta Paediatr Taiwan. 2004. In vitro antibiotic susceptibility of lactobacilli isolated from commercial products containing active lactobacilli. PubMed
- [17] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
- [18] J A Vanderhoof et al.. J Pediatr. 1999. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. doi:10.1016/s0022-3476(99)70053-3 PubMed
- [19] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.